BILE ACID RECEPTOR

Investigational

Approval Year

Substance Class	Protein Created by `admin` on `Tue Apr 01 17:44:15 GMT 2025` Edited by `admin` on `Tue Apr 01 17:44:15 GMT 2025`
Protein Type	RECEPTOR
Protein Sub Type
Sequence Origin	HUMAN
Sequence Type	COMPLETE
Record UNII	0C5V0MRU6P
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

BILE ACID RECEPTOR

Common Name

English

BILE ACID RECEPTOR (HUMAN)

Preferred Name

English

FARNESOID X-ACTIVATED RECEPTOR

Common Name

English

RXR-INTERACTING PROTEIN 14

Common Name

English

RETINOID X RECEPTOR-INTERACTING PROTEIN 14

Common Name

English

FXR (HUMAN)

Common Name

English

FARNESOID X RECEPTOR

Common Name

English

NUCLEAR RECEPTOR SUBFAMILY 1 GROUP H MEMBER 4

Systematic Name

English

NR1H4

Common Name

English

FXR

Common Name

English

Code System Code Type Description

FDA UNII

0C5V0MRU6P

Created by admin on Tue Apr 01 17:44:15 GMT 2025 , Edited by admin on Tue Apr 01 17:44:15 GMT 2025

PRIMARY

Related Record Type Details


					YUN2306954

CILOFEXOR

AGONIST -> TARGET


					TUU8G1CX9O

Danifexor

AGONIST -> TARGET

Amount:


					CJ1PL0TE6J

NIDUFEXOR

AGONIST -> TARGET

Amount:


					0462Z4S4OZ

OBETICHOLIC ACID

AGONIST -> TARGET


					0C33IBK195

VX-984

AGONIST -> TARGET

Amount:


					K3K2F4N8BY

Lecufexor

AGONIST -> TARGET

Amount:


					VVA2ZDV3LX

TERN-101

AGONIST -> TARGET


					724L30Y2QR

URSODIOL

AGONIST -> TARGET

Comments:

When bound to bile acids, FXR repressed transcription of the gene encoding cholesterol 7α-hydroxylase, which is the rate-limiting enzyme in bile acid synthesis, and activated the gene encoding intestinal bile acid?binding protein, which is a candidate bile acid transporter.

Interaction Type:

AGONIST


					MY2RVH3C9D

INT-767 Free Acid

AGONIST -> TARGET

Comments:

Alpha screen

Amount:


					NMZ08KM76Z

TROPIFEXOR

AGONIST -> TARGET


					G9IB4Q8R5G

HPG-1860

AGONIST -> TARGET

Comments:

Time-resolved fluorescence resonance energy (TR-FRET)

Interaction Type:

BINDING

Qualification:

EC50

Amount:


					S6KDM312I5

TUROFEXORATE ISOPROPYL

AGONIST -> TARGET

Amount:


					E05WEZ4XLE

Omesdafexor

AGONIST -> TARGET

Amount:


					JM8C1SFX0U

Danicopan

INHIBITOR->OFF-TARGET

Comments:

Inhibition of the FXR by danicopan has the potential to promote cholestasis.

Amount:


					YO3W29IM33

BMS-986318

AGONIST -> TARGET

Comments:

GAL-4 ASSAY

Amount:


					0GEI24LG0J

CHENODIOL

AGONIST -> TARGET

Comments:

CDCA, had a half-maximal effective concentration (EC50) of 50 mMand 10 micromolar murine and human FXR, respectively (Fig. 1B). These concentrations are well within the physiologic intracellular range reported in vivo (11).

Interaction Type:

AGONIST

Qualification:

IC50

Amount:


					0GEI24LG0J

CHENODIOL

AGONIST -> TARGET


					6TU6SUZ3BY

PX-20606

AGONIST -> TARGET


					A4PW148END

GUGGULSTERONE

INHIBITOR -> TARGET

Qualification:

IC50

Amount:


					XG6DG6A1UN

VONAFEXOR

AGONIST -> TARGET

Structural Modifications

Modification Type	Location Site	Residue Modified	Fragment Name	Fragment Approval
AMINO ACID REPLACEMENT	[1_145] [1_164]	SERINE	DEXFOSFOSERINE	VI4F0K069V
AMINO ACID REPLACEMENT	[1_456]	THREONINE	THREONINE PHOSPHATE	3L4WX7B1EI
AMINO ACID REPLACEMENT	[1_167] [1_227]	LYSINE	N6-ACETYLLYSINE	470AD5VY1X
AMINO ACID REPLACEMENT	[1_220]	LYSINE	N6-METHYLLYSINE	FCR6T2IYVU

Name	Property Type	Amount	Referenced Substance	Defining	Parameters	References
MOL_WEIGHT:NUMBER AVERAGE(CALCULATED)	CHEMICAL